<DateSubmitted>

HOUSE OF REPRESENTATIVES CONFERENCE COMMITTEE REPORT

Mr. President: Mr. Speaker:

The Conference Committee, to which was referred

HB2510

Kannady of the House and Thompson of the Senate By:

Title: Opioid abatement; Political Subdivisions Opioid Abatement Grants Act; criteria for allocating opioid grant awards; emergency.

Together with Engrossed Senate Amendments thereto, beg leave to report that we have had the same under consideration and herewith return the same with the following recommendations:

- 1. That the Senate recede from its amendment: and
- 2. That the attached Conference Committee Substitute be adopted.

Respectfully submitted,

HB2510 CCR A **SENATE CONFEREES:** GCCA (must be signed out at a Senate GCCA meeting)

Brooks		Matthews	
Dossett		Montgomery	
Dugger		Newhouse	
Floyd		Pederson	
Hall		Pemberton	
Haste		Rader	
Howard		Rosino	
Jech		Simpson	
Kidd		Weaver	
Kirt		Thompson	

1	STATE OF OKLAHOMA				
2	1st Session of the 58th Legislature (2021)				
3	CONFERENCE COMMITTEE				
4	SUBSTITUTEFOR ENGROSSEDHOUSE BILL NO. 2510By: Kannady of the House				
5					
6	and				
7	Thompson of the Senate				
8					
9	CONFERENCE COMMITTEE SUBSTITUTE				
10	An act relating to opioid abatement; amending Sections 3 and 6, Chapter 130, O.S.L. 2020 (74 O.S. Supp. 2020, Sections 30.5 and 30.8), which relate to the Political Subdivisions Opioid Abatement Grants Act; modifying scope of certain defined terms; deleting definition; revising criteria for allocating opioid grant awards to eligible participants; eliminating requirement for legal services agreements; requiring initial opioid grant awards to be listed on a distribution table; and declaring an				
11					
12					
13					
14					
15	emergency.				
16					
17	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:				
18	SECTION 1. AMENDATORY Section 3, Chapter 130, O.S.L.				
19	2020 (74 O.S. Supp. 2020, Section 30.5), is amended to read as				
20	follows:				
21	Section 30.5 As used in the Political Subdivisions Opioid				
22	Abatement Grants Act:				
23	1. "Approved purpose" and "approved purposes" mean evidence-				
24	based, forward-looking strategies, programming and services used to:				
	•				

1 expand the availability of treatment for individuals a. 2 affected by opioid use disorders, co-occurring substance use disorders and mental health issues, 3 4 b. develop, promote and provide evidence-based opioid use 5 prevention strategies, provide opioid use disorder and co-occurring substance 6 с. 7 use disorder avoidance and awareness education, d. decrease the oversupply of licit and illicit opioids, 8 9 support recovery from addiction services performed by e. 10 qualified and appropriately licensed providers, 11 f. treat opioid use, abuse and disorders, including early 12 intervention screening, counseling and support, 13 support individuals in treatment and recovery from g. 14 opioid use, abuse and disorder, 15 provide programs or services to connect individuals h. 16 with opioid use, abuse or disorder, or who are at risk 17 of developing opioid use disorder, co-occurring 18 substance use disorder and mental health issues, with 19 treatment and counseling programs and services, 20 i. address the needs of individuals who are involved, or 21 who are at risk of becoming involved, in the criminal 22 justice system due to opioid use, abuse or disorder 23 through programs or services in municipal and county 24 criminal judicial systems, including prearrest and

Page 2

postarrest diversion programs, pretrial services and drug or recovery courts,

- 3 j. address the needs of pregnant or parenting women with 4 opioid use, abuse or disorder and their families \overline{r} 5 including babies with neonatal abstinence syndrome,
- address the needs of parents and caregivers caring for k. 7 babies with neonatal abstinence syndrome,
 - support efforts to prevent overprescribing and ensure l. appropriate prescribing and dispensing of opioids,
- 10 support efforts to discourage or prevent misuse of l. m. 11 opioids, including the oversupply of licit and illicit 12 opioids,
- 13 support efforts to prevent or reduce overdose deaths m. n. 14 or other opioid-related harms, including through 15 increased availability and distribution of naloxone 16 and other drugs that treat overdoses for use by first 17 responders, persons who have experienced an overdose 18 event, families, schools, community-based service 19 providers, social workers and other members of the 20 public,
- 21 reimburse or fund law enforcement and emergency n. o. 22 responder expenditures relating to the opioid 23 epidemic, including costs of responding to emergency 24 medical or police calls for service, equipment,

1

2

6

8

9

Page 3

1 treatment or response alternatives, mental health 2 response training and training for law enforcement and 3 emergency responders as to appropriate practices and 4 precautions when dealing with opioids or individuals 5 who are at risk of opioid overdose or death, 6 reimburse attorney fees and expenses directly related o. p. 7 to opioid litigation incurred as part of legal 8 services agreements entered into before May 21, 2020, 9 support efforts to provide leadership, planning and q. 10 coordination to abate the opioid epidemic through 11 activities, programs or strategies for prevention and 12 recovery models, including regional intergovernmental 13 efforts and not-for-profit agency support, 14 support education of youths regarding the dangers of p. r. 15 opioid use, abuse and addiction, 16 fund training relative to any approved purpose, q. s. 17 monitor, surveil and evaluate opioid use, abuse or r. t. 18 disorder, or 19 provide opioid abatement as identified by the Oklahoma s. u. 20 Opioid Abatement Board as consistent with the purpose 21 of this act the Political Subdivisions Opioid 22 Abatement Grants Act. 23 Provided that such strategies, programming and services occurred on 24 or after January 1, 2006 2015;

2. "Board" means the Oklahoma Opioid Abatement Board;
 3. "Eligible participant" means any political subdivision or
 first responder organization that obtained legal representation or
 participated in litigation with pharmaceutical supply chain
 participants prior to the effective date of this act negatively
 impacted by the opioid crisis;

7 4. "First responder organization" means a nonprofit
8 organization formed and in good standing under 501(c)(9) of the
9 Internal Revenue Code, whose primary function is to benefit public
10 safety employees;

11 5. "Nonapproved purpose" and "nonapproved purposes" mean 12 strategies, programming and services not falling within the 13 definition of "approved purpose" or "approved purposes" as defined 14 in this act section;

15 6. 5. "Opioid funds" means all monetary amounts obtained 16 through a settlement or judgment by the Attorney General on behalf 17 of the State of Oklahoma related to opioid litigation involving 18 pharmaceutical supply chain participants, including the Purdue 19 Political Subdivisions Fund but excluding all other funds received 20 pursuant to the Purdue Settlement Agreement;

21 7. 6. "Opioid grant awards" means grants funded from the 22 Oklahoma Opioid Abatement Revolving Fund, awarded pursuant to the 23 provisions of this act the Political Subdivisions Opioid Abatement 24 Grants Act;

Req. No. 8267

Page 5

8. 7. "Pharmaceutical supply chain" means the process and
 channels through which controlled substances are manufactured,
 marketed, promoted, distributed or dispensed;

9. 8. "Pharmaceutical supply chain participant" means any
entity that engages in or has engaged in the manufacture, marketing,
promotion, distribution or dispensing of an opioid analgesic;

7 10. 9. "Political subdivision" and "political subdivisions" have the same meaning as provided in subparagraphs a, b, c and d of 8 9 paragraph 11 of Section 152 of Title 51 of the Oklahoma Statutes; 10 11. 10. "Purdue Political Subdivision Fund" means the Twelve 11 Million Five Hundred Thousand Dollars (\$12,500,000.00) plus any 12 interest accrued thereon received from the Revive Oklahoma Health 13 Foundation consisting of funds from the Purdue Settlement Agreement 14 designed for distribution to political subdivisions which have executed a release of legal claims as required by the Purdue 15 16 Settlement Agreement; and

17 <u>12. 11.</u> "Purdue Settlement Agreement" means the settlement
18 agreement entered into by the State of Oklahoma and Purdue Pharma
19 L.P., Purdue Pharma, Inc. and the Purdue Frederick Company on March
20 26, 2019, and approved by the Court on April 2, 2019.
21 SECTION 2. AMENDATORY Section 6, Chapter 130, O.S.L.

22 2020 (74 O.S. Supp. 2020, Section 30.8), is amended to read as 23 follows:

24

1 Section 30.8 A. 1. The Oklahoma Opioid Abatement Board shall 2 conduct an initial disbursement of opioid grant awards to 3 participating eligible participants. Such opioid grant awards shall 4 be allocated amongst the different participating eligible 5 participants based on the following criteria, giving equal weight to each criteria: 6 7 the number of people per capita suffering from opioid a. use disorder in the participating political 8 9 subdivision, or in the absence of such information, 10 the opioid prescription rate in the political 11 subdivision compared to the national average opioid 12 prescription rate, 13 the number of opioid overdose deaths in the b. 14 participating political subdivision, and 15 the amount of opioids distributed within the C. 16 participating political subdivision adopted by the 17 Board. 18 2. Grant awards shall be subject to legal services agreements 19 entered into by participating eligible participants based on the 20 grant awards. 21 3. Initial opioid grant awards as provided for in this 22 subsection shall be listed in an opioid grant award allocation 23 matrix distribution table reviewed and approved by the Board to 24

Req. No. 8267

ensure that such awards adhere to the criteria as provided in this
 subsection adopted by the Board.

B. Following the awarding of opioid grant awards pursuant to subsection A of this section, any remaining unencumbered balance in the Oklahoma Opioid Abatement Revolving Fund shall be available to the Board to award as grants to eligible participants; provided such awards shall only be utilized by eligible participants for approved purposes.

9 C. In the event an eligible participant merges, dissolves or 10 ceases to exist, any remaining allocations of an awarded opioid 11 grant award in excess of Five Hundred Dollars (\$500.00) shall be 12 reallocated equitably based on the composition of the successor 13 eligible participant or the successor eligible participants.

14 SECTION 3. It being immediately necessary for the preservation 15 of the public peace, health or safety, an emergency is hereby 16 declared to exist, by reason whereof this act shall take effect and 17 be in full force from and after its passage and approval.

18

19 58-1-8267 GRS 05/10/21

21

20

22

23

24